Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Guidelines for the management of diffuse large B-cell lymphoma.

× No keyword cloud information.

38 in total

1. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.

Authors: Maziar Moradi-Lakeh; Mohsen Yaghoubi; Patrick Seitz; Mehdi Javanbakht; Elisabeth Brock
Journal: Adv Ther Date: 2021-05-22 Impact factor: 3.845

Review 2. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Authors: Richard J Lin; Madhusmita Behera; Catherine S Diefenbach; Christopher R Flowers
Journal: Blood Date: 2017-08-16 Impact factor: 22.113

Review 3. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Authors: P Skrabek; S Assouline; A Christofides; D MacDonald; A Prica; R Sangha; B A Matthews; L H Sehn
Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677

4. Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study.

Authors: Takanori Fukuta; Noriko Nishimura; Yuko Shirouchi; Norihito Inoue; Hideki Uryu; Yoshiharu Kusano; Yuko Mishima; Masahiro Yokoyama; Naoko Tsuyama; Kengo Takeuchi; Yasuhito Terui
Journal: Int J Hematol Date: 2020-01-14 Impact factor: 2.490

5. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.

Authors: Andre Goy; Radhakrishnan Ramchandren; Nilanjan Ghosh; Javier Munoz; David S Morgan; Nam H Dang; Mark Knapp; Maria Delioukina; Edwin Kingsley; Jerry Ping; Darrin M Beaupre; Jutta K Neuenburg; Jia Ruan
Journal: Blood Date: 2019-07-22 Impact factor: 22.113

Review 6. Personalized treatment of malignant tumors during pregnancy.

Authors: E Ulrikh; E Kalinina; E Dikareva; E Komlichenko; O Li; O Zhamborova; I Rizhinashvili; A Dzharbaeva; I Govorov; V Artemenko; V Bezrukikh; G Salogub; T Pervunina; A Urmancheeva
Journal: Medicine (Baltimore) Date: 2022-07-01 Impact factor: 1.817

7. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors: Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal: Cancer Date: 2019-02-01 Impact factor: 6.860

8. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.

Authors: Francesco Marchesi; Giulia Regazzo; Francesca Palombi; Irene Terrenato; Andrea Sacconi; Manuela Spagnuolo; Sara Donzelli; Mirella Marino; Cristiana Ercolani; Anna Di Benedetto; Giovanni Blandino; Gennaro Ciliberto; Andrea Mengarelli; Maria Giulia Rizzo
Journal: J Exp Clin Cancer Res Date: 2018-05-02

9. Understanding the Feasibility of Implementing CAR T-Cell Therapies from a Canadian Perspective.

Authors: Kristina Ellis; Kelly Grindrod; Stephen Tully; Tom McFarlane; Kelvin K W Chan; William W L Wong
Journal: Healthc Policy Date: 2021-02

Review 10. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.

Authors: Faroogh Marofi; Heshu Sulaiman Rahman; Muhammad Harun Achmad; Klunko Nataliya Sergeevna; Wanich Suksatan; Walid Kamal Abdelbasset; Maria Vladimirovna Mikhailova; Navid Shomali; Mahboubeh Yazdanifar; Ali Hassanzadeh; Majid Ahmadi; Roza Motavalli; Yashwant Pathak; Sepideh Izadi; Mostafa Jarahian
Journal: Front Immunol Date: 2021-06-23 Impact factor: 7.561